Patent 11129826 was granted and assigned to Axsome Therapeutics on September, 2021 by the United States Patent and Trademark Office.
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.